GENE ONLINE|News &
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
Recent research presented at the European Society of Cardiology Heart Failure 2026 Congress examined the therapeutic potential of digitalis glycosides for patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with reduced ejection fraction (HFrEF). The study focused on evaluating both the effectiveness and safety of these medications in treating these conditions.
The study provided insights into how digitalis glycosides may benefit individuals with both HFmrEF and HFrEF. Researchers analyzed data to determine the impact of the drugs on heart function and overall patient outcomes. The findings contribute to the ongoing discussion about the role of digitalis glycosides in contemporary heart failure management.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: May 10, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Hilton Partners With Big Brothers Big Sisters to Provide Hospitality Career Training for Youth
2026-06-18
Pacific Life Launches Income Horizon Collective Investment Trust Series for Retirement Plans
2026-06-18
Synovis Micro Companies Alliance to Distribute MediThinQ SHIYA 3D Visualization Platform Globally
2026-06-18
Diamond Estates Wines & Spirits Inc. Renews Investor Relations Agreement with Atrium Research
2026-06-18
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
